Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DCK | P27707 | 2/20 | 0.40 |
| ▸ | ATR | Q13535 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.39 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.39 |
| ▸ | FEN1 | P39748 | 4/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18936946 | 0.90 | MAPK1 (0.48) | KCNH2PIK3CGPIK3CAMAPK1DCK | |
| SCHEMBL18937013 | 0.83 | MAPK1 (0.40) | KCNH2MAPK1ATRALOX5APFEN1 | |
| SCHEMBL12496236 | 0.81 | GABRG2 (0.47) | KCNH2MAPK1ATRALOX5APFEN1 | |
| SCHEMBL12495772 | 0.81 | KCNH2 (0.45) | KCNH2PIK3CGPIK3CAATRPIK3CD | |
| SCHEMBL12495960 | 0.81 | KCNH2 (0.43) | KCNH2PIK3CGPIK3CAMAPK1DCK | |
| SCHEMBL18936996 | 0.80 | ATR (0.47) | MAPK1ATR | |
| Hydrochloric Acid SCHEMBL12077643 | 0.80 | MAPK1 (0.43) | KCNH2MAPK1ATR | |
| SCHEMBL12078765 | 0.80 | KCNH2 (0.59) | KCNH2PIK3CGMAPK1PIK3CDPIK3CB | |
| SCHEMBL12496015 | 0.79 | GSK3B (0.44) | KCNH2PIK3CGPIK3CAMAPK1ATR | |
| SCHEMBL12495977 | 0.78 | MAPK1 (0.53) | KCNH2PIK3CGMAPK1PIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | claimed |
| EP-2681206-B1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2681206-B1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2014-02-20 | — | — | US | disclosed |
| EP-2681206-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2012121992-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012121992-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | KCNH2 4765/4885PIK3CG 865/4885PIK3CA 725/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | KCNH2 2482/4885PIK3CG 2013/4885PIK3CA 2169/4885 |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | KCNH2 4765/4885PIK3CG 865/4885PIK3CA 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.